UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations

Cancer discovery, 2014-09, Vol.4 (9), p.1036-1045

2014

Volltextzugriff (PDF)

Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives

Cancer treatment reviews, 2018-05, Vol.66, p.104-113

2018

Volltextzugriff (PDF)

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

Journal for immunotherapy of cancer, 2018-10, Vol.6 (1), p.111-111, Article 111

2018

Volltextzugriff (PDF)

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma

Lung cancer (Amsterdam, Netherlands), 2015-04, Vol.88 (1), p.63-69

2015

Volltextzugriff (PDF)

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

Clinical cancer research, 2021-03, Vol.27 (6), p.1631-1640

2021

Volltextzugriff (PDF)

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib

Lung cancer (Amsterdam, Netherlands), 2017-11, Vol.113, p.51-58

2017

Volltextzugriff (PDF)

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Journal for immunotherapy of cancer, 2019-02, Vol.7 (1), p.30-30, Article 30

2019

Volltextzugriff (PDF)

Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation

Cancer, 2013-08, Vol.119 (16), p.3043-3051

2013

Volltextzugriff (PDF)

Allocation of Taxing Rights in the Digitalized Economy: Assessment of Potential Policy Solutions and Recommendation for a Simplified Residual Profit Split Method

Intertax, 2019-01, Vol.47 (Issue 12), p.1023-1041

Chand, Vikram

2019

Volltextzugriff (PDF)

Pillar I: The Marketing and Distribution Safe Harbour (MDSH) as Applicable to Licensed Manufacturers and Centralized Business Models: Does It Fulfil Its Policy Objective?

Intertax, 2023-08, Vol.51 (Issue 8/9), p.572-594

2023

Volltextzugriff (PDF)

A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors

Investigational new drugs, 2014-12, Vol.32 (6), p.1226-1235

2014

Volltextzugriff (PDF)

Editorials: Achieving Certainty in an Uncertain Profit Allocation Environment

Intertax, 2019-12, Vol.47 (Issue 12), p.1000-1002

Chand, Vikram

2019

Volltextzugriff (PDF)

The Principal Purpose Test in the Multilateral Convention: An in-depth Analysis

Intertax, 2018-01, Vol.46 (Issue 1), p.18-44

Chand, Vikram

2018

Volltextzugriff (PDF)

Transfer Pricing Aspects of Intra - Group Loans in Light of the Base Erosion and Profit Shifting Action Plan

Intertax, 2016-12, Vol.44 (Issue 12), p.885-902

Chand, Vikram

2016

Volltextzugriff (PDF)

The Interaction of the Principal Purpose Test (and the Guiding Principle) with Treaty and Domestic Anti-Avoidance Rules

Intertax, 2018-01, Vol.46 (Issue 2), p.115-123

Chand, Vikram

2018

Volltextzugriff (PDF)

A Long-Term Solution for Taxing Digitalized Business Models: Should the Permanent Establishment Definition Be Modified to Resolve the Issue or Should the Focus Be on a Shared Taxing Rights Mechanism?

Intertax, 2018-01, Vol.46 (Issue 6/7), p.476-494

Spinosa, Lisa

2018

Volltextzugriff (PDF)

Stałe zakłady w świetle Filarów – znaczenie analizy cen transferowych

Analizy i Studia CASP, 2024-03, Vol.15 (1), p.31-42

2024

Volltextzugriff (PDF)

Curative-Intent Treatment with Durvalumab in Early-Stage Cancers

Advances in therapy, 2021-06, Vol.38 (6), p.2759-2778

2021

Volltextzugriff (PDF)

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

JAMA oncology, 2019-03, Vol.5 (3), p.393

2019

Volltextzugriff (PDF)

Permanent Establishments under the Pillars: The Relevance of a Transfer Pricing Analysis

Analizy i Studia CASP, 2023, Vol.15 (1), p.31-42

2023

Volltextzugriff (PDF)

Application of the Arms Length Principle to Physical Cash Pooling Arrangements in Light of the OECD Discussion Draft on Financial Transactions

Intertax, 2019-04, Vol.47 (Issue 4), p.349-364

Haller, Alexander

2019

Volltextzugriff (PDF)

Country Note: Arm’s Length Principle from a Swiss Perspective: Profit Allocation to Inbound and Outbound Permanent Establishments

Intertax, 2022-01, Vol.50 (Issue 1), p.66-81

2022

Volltextzugriff (PDF)

1 – 25 von 188

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(148)
Mit Volltextzugriff
(147)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(186)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(82)
Life Sciences & Biomedicine
(45)
Physical Sciences
(35)
Physics
(33)
Humans
(31)
Physics, Applied
(23)
Female
(18)
Oncology
(16)
Male
(15)
Middle Aged
(14)
Exact Sciences And Technology
(13)
Technology
(13)
Physics, Condensed Matter
(12)
Adult
(11)
Social Sciences
(10)
Applied Sciences
(9)
Materials Science
(9)
Materials Science, Multidisciplinary
(9)
Aged
(8)
Government & Law
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations

Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation

Allocation of Taxing Rights in the Digitalized Economy: Assessment of Potential Policy Solutions and Recommendation for a Simplified Residual Profit Split Method

Pillar I: The Marketing and Distribution Safe Harbour (MDSH) as Applicable to Licensed Manufacturers and Centralized Business Models: Does It Fulfil Its Policy Objective?

A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors

Editorials: Achieving Certainty in an Uncertain Profit Allocation Environment

The Principal Purpose Test in the Multilateral Convention: An in-depth Analysis

LUX-Lung 8: A Global Phase III Trial of Afatinib (A) vs Erlotinib (E) as Second-Line Treatment in Patients (Pts) With Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy

Transfer Pricing Aspects of Intra - Group Loans in Light of the Base Erosion and Profit Shifting Action Plan

The Interaction of the Principal Purpose Test (and the Guiding Principle) with Treaty and Domestic Anti-Avoidance Rules

A Long-Term Solution for Taxing Digitalized Business Models: Should the Permanent Establishment Definition Be Modified to Resolve the Issue or Should the Focus Be on a Shared Taxing Rights Mechanism?

Stałe zakłady w świetle Filarów – znaczenie analizy cen transferowych

Curative-Intent Treatment with Durvalumab in Early-Stage Cancers

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

Permanent Establishments under the Pillars: The Relevance of a Transfer Pricing Analysis

Application of the Arms Length Principle to Physical Cash Pooling Arrangements in Light of the OECD Discussion Draft on Financial Transactions

Country Note: Arm’s Length Principle from a Swiss Perspective: Profit Allocation to Inbound and Outbound Permanent Establishments

Suchergebnisse filtern